Exploring the Matterhorn Trial: Combining Immunotherapy with Standard Care for Gastric Cancer

This chapter reviews the ASCO 2025 plenary presentation on the Matterhorn trial, highlighting the combination of Dervalumab with the FLOT regimen for patients with resectable gastric cancers. It discusses trial outcomes, current standards of care, and the implications for future treatment options pending further research and FDA approval.